Dexmedetomidine for Postoperative Analgesia After Bariatric Surgery

American University of Beirut Medical Center

Status and phase: Completed; Phase 3; Phase 2

Conditions: Hypertension; Diabetes; Obesity; Sleep Apnea

Treatments: Drug: Morphine; Drug: Dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT02213159

ANES.CZ.2

Details and patient eligibility

About

The purpose of this study is to determine if Dexmedetomidine given at the end of surgery will reduce postoperative morphine consumption and improve postoperative quality of recovery as compared to morphine in patients undergoing laparoscopic bariatric surgery.

Full description

effect of Dexmedetomidine bolus on postoperative morphine requirements

Enrollment: 60 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Body Mass Index > 40 kg/m2 or BMI > 35 kg/m2 with comorbid conditions such as hypertension, diabetes or sleep apnea
• American Society of Anesthesiologists class I or II
• Undergoing laparoscopic sleeve gastrectomy bariatric surgery

Exclusion criteria

• Allergy to morphine or its derivatives
• Allergy to α-2 adrenergic agonists
• weight over 180 kg
• history of uncontrolled hypertension
• heart block greater than first degree
• prolonged QT interval
• clinically significant neurologic, cardiovascular, renal, hepatic, or gastrointestinal diseases
• received an opioid analgesic medication within a 24 h period prior to surgery
• history of alcohol, drug abuse or chronic opioid intake
• history of psychiatric disorder
• pregnant or breastfeeding.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups

Dexmedetomidine

Active Comparator group

Description:

prior to anticipated end of surgery bolus of 1 microgram/kg Dexmedetomidine intravenously over 10 minutes followed by 0.5 micrograms/kilogram/hour intravenous infusion until removal of laparoscopes

Treatment:

Drug: Dexmedetomidine

Morphine

Active Comparator group

Description:

prior to anticipated completion of surgery morphine 0.08 mg/kilogram intravenous bolus over 10 minutes followed by a saline infusion until removal of the laparoscopes

Treatment:

Drug: Morphine